Prostate Cancer | Patterns of Care: Understanding and Optimizing the Current Management of Metastatic Prostate Cancer in the Real World

published 1 month ago by Dr Neil Love

Featuring a roundtable discussion with Drs Andrew J Armstrong, Celestia S Higano, David F Penson and Neal D Shore on the following topics: Optimizing the Choice of Therapy for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Selection of chemotherapy or secondary hormonal therapy (enzalutamide, abiraterone, apalutamide) to administer with androgen deprivation therapy (ADT) (0:00) Management of HSPC in patients with de novo asymptomatic metastases (9:04) Use of secondary hormonal therapy or chemotherapy in addition to ADT for patients with mHSPC in community-based practices (15:53) Effect of patient age and comorbidities on choice of therapy for mHSPC (21:15) Clinical outcomes with the addition of chemotherapy or secondary hormonal therapy to ADT for patients with mHSPC (29:42) Tolerability and side-effect profiles of abiraterone/prednisone and enzalutamide (33:32) Paradigm shift in the management of mHSPC — Neal D Shore, MD (37:36) Case: A man in his late 60s with mHSPC achieves a good clinical response to ADT and apalutamide (53:51) Case: A man in his early 50s with HSPC and extensive bone metastases (55:11) Overall survival outcomes with the addition of secondary hormonal therapy or chemotherapy to ADT; management of the primary tumor in patients with mHSPC (57:35) Practical factors influencing the selection of therapy for patients with mHSPC — David F Penson, MD, MPH, MMHC (1:02:39) Case: A man in his late 50s with mHSPC and a BRCA2 mutation receives abiraterone and prednisone after treatment with docetaxel and ADT (1:21:49) Balancing the risks and benefits of secondary hormonal therapy (1:25:47) Selection and Sequencing of Therapies for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Choice of therapy based on symptoms and site of metastases for patients with mCRPC (1:27:28) Management of mCRPC after disease progression on secondary hormonal therapy; testing for AR-V7 to predict resistance (1:32:29) Clinical experience with the PARP inhibitors olaparib and rucaparib; activity of cabazitaxel in patients with mCRPC (1:36:54) Recent FDA approval of rucaparib and olaparib for mCRPC; implications for genetic testing and routine practice (1:39:40) Sequencing of therapies for men with mCRPC — Celestia S Higano, MD (1:46:36) Promising agents and strategies for men with metastatic prostate cancer — Andrew J Armstrong, MD, ScM (2:04:40) CME information and select publications

more episodes from Research To Practice | Oncology Videos